# Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

> **NCT00975806** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 16 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00975806
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09-01
- **Primary completion:** 2011-10-01
- **Final completion:** 2011-10-01
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00975806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00975806, "Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00975806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*